Who owns Zogenix?
Who owns Zogenix?
Top 10 Owners of Zogenix Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Morgan Stanley & Co. LLC | 7.37% | 4,114,512 |
| BlackRock Fund Advisors | 7.26% | 4,049,379 |
| The Vanguard Group, Inc. | 7.09% | 3,956,557 |
| Cadian Capital Management LP | 5.69% | 3,175,431 |
When was zogenix founded?
2006
Zogenix/Founded
In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products. Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006.
Where is zogenix located?
Emeryville
Zogenix is headquartered in Emeryville, CA and has 2 office locations across 2 countries.
How many employees does zogenix have?
Company Growth (employees)
| Employees (est.) (Dec 2019) | 141 | (+57%) |
|---|---|---|
| Website Visits (Apr 2021) | 7.2 k | |
| Revenue (FY, 2020) | $13.6 M | (+274%) |
| Share Price (Aug 2021) | $13.8 | (+2%) |
| Cybersecurity rating | A | More |
Is Fintepla approved?
The U.S. Food and Drug Administration today approved Fintepla (fenfluramine), a Schedule IV controlled substance, for the treatment of seizures associated with Dravet syndrome in patients age 2 and older. Dravet syndrome is a life-threatening, rare and chronic form of epilepsy.
What is Dravet syndrome?
Definition. Dravet syndrome, previously called severe myoclonic epilepsy of infancy (SMEI), is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.
Is zogenix a good company?
Great company, everyone is very smart and dedicated. The people at Zogenix are amazing. Culture is very important to the company and the leadership keeps culture in mind before making large business decisions. There is so much potential for Zogenix coming in the future.
Who makes Fintepla?
About Zogenix The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, C-IV has been approved by the U.S. FDA and is under review in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy.